美多巴联合普拉克索治疗帕金森病的临床疗效观察

Feasibility and Safety of Madopar Combined with Pramipexole in the Treatment of Parkinson's Disease

目的:探讨美多巴联合普拉克索治疗帕金森病的可行性及安全性。方法:选取2014年1月至2015年10月鹰潭市人民医院的98例帕金森病患者,随机分为研究组和对照组,每组49例。对照组使用单纯美多巴治疗,研究组使用美多巴联合普拉克索治疗。比较两组患者的治疗总有效率、治疗前后UPDRS评分和不良反应发生率的差异。结果:研究组的治疗总有效率为98.0%,比对照组的高(P<0.05);治疗前,两组UPDRS评分比较无统计学差异(P>0.05);治疗后,研究组UPDRSⅡ和UPDRSⅢ评分均低于对照组(P<0.05);两组不良反应发生率比较无统计学差异(P>0.05)。结论:美多巴联合普拉克索治疗帕金森病效果好,不良反应少,值得临床推广使用。

Objective： To investigate feasibility and safety of madopar combined with pramipexole in the treatment of Parkinson＇s disease.Methods： 98 cases of Parkinson＇s disease patients in People＇s Hospital of Yingtan City were randomly divided into research group and control group. The control group was treated with madopar, while research group were treated with madopar combined with pramipexole. The total effective rate, UPDRS score before and after treatment and adverse effects rate of two groups were compared.Results： The total effective rate of research group were higher than control group （P〈0.05）. Before treatment, the UPDRS score of two groups has no significant difference （P〉0.05）. The UPDRSⅡ score and UPDRSⅢ score of research group were lower than control group （P〈0.05）. There was no significant difference in adverse effects rate between two groups （P〈0.05）.Conclusion： Madopar combined with pramipexole treatment has exact effect for Parkinson＇s disease with high total effective rate and low adverse effects rate. And it should be widely used.